HIV感染者停用含替诺福韦艾拉酚胺抗逆转录病毒治疗后的体重、人体测量学及代谢变化
在瑞士HIV队列研究中,6555名接受含替诺福韦艾拉酚胺(TAF)方案至少6个月的HIV感染者中,停用TAF者12个月后调整平均体重变化为-0.54 kg(95%CI -0.98至-0.11)。转换为替诺福韦二吡呋酯(TDF)者体重下降1.84 kg并改善血脂,而转换为多替拉韦/拉米夫定或长效卡博特韦/利匹韦林者未见体重下降。
要点
- 停用TAF与12个月时调整平均体重下降0.54 kg相关(95%CI -0.98至-0.11)。
- TAF转换为TDF者体重下降1.84 kg(95%CI -2.72至-0.97),总胆固醇和甘油三酯亦下降。
- 转换为多替拉韦/拉米夫定或长效卡博特韦/利匹韦林者未见体重下降。
核心结论
- 在HIV感染者中,将TAF替换为TDF可在1年内导致体重下降并改善血脂谱。
- 转换为多替拉韦/拉米夫定或长效卡博特韦/利匹韦林者未观察到体重变化。
研究设计与样本
- 瑞士HIV队列研究,纳入2016年1月至2023年3月期间接受含TAF方案至少6个月的参与者。
- 共6555名参与者,中位年龄54岁,女性占24.3%,黑人占13%;5485人(83.7%)继续TAF,1070人(16.3%)停用TAF。
- 采用多变量混合效应模型比较继续TAF者与转换为无TAF方案者的体重和血脂水平变化。
主要发现
- 停用TAF与12个月时调整平均体重变化-0.54 kg相关(95%CI -0.98至-0.11)。
- TAF转换为TDF者12个月时调整平均体重下降1.84 kg(95%CI -2.72至-0.97),平均总胆固醇下降0.44 mmol/L,甘油三酯下降0.38 mmol/L。
- TAF转换为多替拉韦/拉米夫定者体重变化-0.17 kg(95%CI -0.82至0.48),转换为长效卡博特韦/利匹韦林者体重变化-0.64 kg(95%CI -2.16至0.89),均未导致体重下降。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antiretroviral therapy (ART)-related weight gain is of particular concern in people with HIV (PWH). Although weight gain was observed among PWH receiving tenofovir alafenamide (TAF), little is known about the potential reversibility after TAF discontinuation. We evaluated weight and metabolic changes 12 months after TAF discontinuation in the Swiss HIV Cohort Study. METHODS: We included participants who received at least 6 months of TAF-containing ART between January 2016 and March 2023. Using multivariable mixed-effect models, changes in weight and lipid levels were compared between individuals who continued TAF and those who switched to one of the following TAF-free regimens: (1) tenofovir disoproxil fumarate (TDF)-based ART, (2) dolutegravir/lamivudine (DTG/3TC), or (3) long-acting cabotegravir/rilpivirine (CAB/RPV). RESULTS: Of 6555 participants (median age 54 years, 24.3% female, 13% Black), 5485 (83.7%) continued, and 1070 (16.3%) stopped TAF. Overall, discontinuing TAF was associated with an adjusted mean weight change of -0.54 kg (95% confidence interval [CI] -.98 to -.11) after 12 months. In stratified analyses, switching from TAF to TDF led to an adjusted mean weight decrease of -1.84 kg (95% CI -2.72 to -.97), and to a decrease in mean total cholesterol (-0.44 mmol/L) and triglycerides (-0.38 mmol/L) after 12 months. Switching from TAF-based ART to DTG/3TC (-0.17 kg, 95% CI -.82 to .48) or long-acting CAB/RPV (-0.64 kg, 95% CI -2.16 to .89) did not lead to reductions in weight. CONCLUSIONS: Replacing TAF with TDF in PWH led to a decrease in body weight and an improved lipid profile within 1 year. Weight changes were not observed among individuals who switched to DTG/3TC or long-acting CAB/RPV.
引用
- Damas J, Munting A, Fellay J, et al. Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide in People With HIV. Clin Infect Dis. 2024. PMID: 38606792. doi:10.1093/cid/ciae189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。